China SXT Pharmaceuticals, Inc. (SXTC) P/E Ratio History
Historical price-to-earnings valuation from 2019 to 2025
Loading P/E history...
SXTC Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, China SXT Pharmaceuticals, Inc. (SXTC) trades at a price-to-earnings ratio of -0.2x, with a stock price of $1.66 and trailing twelve-month earnings per share of $-1.35.
The current P/E is 100% below its 5-year average of 817.6x. Over the past five years, SXTC's P/E has ranged from a low of 24.4x to a high of 2005.1x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, SXTC trades at a 101% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, SXTC trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our SXTC DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
SXTC P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $587M | 31.7 | - | +17% | |
| $134M | 32.2 | 7.51 | +16% | |
| $203B | 12.7Lowest | 0.61Best | +2% | |
| $151B | 19.5 | - | -4% | |
| $277B | 15.4 | 0.73 | +8% | |
| $178B | 23.1 | 7.86 | +88%Best | |
| $358B | 85.5 | - | -1% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
SXTC Historical P/E Data (2019–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | $76.20 | $0.18 | 423.3x | -48% | |
| FY2025 Q2 | Mon Sep 30 2024 00:00:00 GM | $109.50 | $4.49 | 24.4x | -97% |
| FY2019 Q4 | Sun Mar 31 2019 00:00:00 GM | $102300.00 | $51.02 | 2005.1x | +145% |
Average P/E for displayed period: 817.6x
See SXTC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SXTC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SXTC vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSXTC — Frequently Asked Questions
Quick answers to the most common questions about buying SXTC stock.
Is SXTC stock overvalued or undervalued?
SXTC trades at -0.2x P/E, below its 5-year average of 817.6x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does SXTC's valuation compare to peers?
China SXT Pharmaceuticals, Inc. P/E of -0.2x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is SXTC's PEG ratio?
SXTC PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2019-2025.